DUBLIN--(BUSINESS WIRE)--The "Global Human Growth Hormone Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The human growth hormone market will register a CAGR of almost 4% by 2022.
Increasing incidence and prevalence of growth hormone disorders due to the growth hormone deficiency is expected to drive the human growth hormone market over the forecast period. Moreover, various indications fall under the growth hormone disorders such as turner syndrome, growth hormone deficiency, acromegaly, Noonan syndrome, gigantism, and many more.
Strong pipeline of human growth hormone
Many leading companies such as Novo Nordisk, Merck, and Pfizer have a strong pipeline in their portfolio for treating various growth hormone disorders. All these factors are expected to drive the global human growth hormone market during the forecast period.
Poor patient adherence
The poor patient adherence for human growth hormone due to uneasiness with growth hormone administration will impact the treatment adherence and results.
Key Players
- Eli Lilly
- F. Hoffmann-La Roche
- Novo Nordisk
- Pfizer
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY DRUG TYPE
PART 09: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Comparison by application
- Growth hormone deficiency - Market size and forecast 2017-2022
- ISS - Market size and forecast 2017-2022
- Turner syndrome - Market size and forecast 2017-2022
- PWS - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by application
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
- Increasing incidence of growth disorders
- No impact of biosimilar entry into market
- Advanced technologies
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly
- F. Hoffmann-La Roche
- Novo Nordisk
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/mm9bj4/human_growth?w=4
